ClinicalTrials.gg
CompletedNCT04320615COVACTAUpdated Jun 30, 2021Results posted

A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia

A Phase 3 interventional study of Tocilizumab (TCZ) and Placebo in COVID-19 Pneumonia, sponsored by Hoffmann-La Roche. Completed at 62 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-30.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
452
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 38 studies testing tocilizumab in COVID-19 — 3 open to participants now, 4 under way, 2 of them phase 3. tocilizumab · COVID-19.

Enrollment
7th of 38
452 · median 150
Started
2020
with 33 others
Phase 3
13 of 38
2 open now
Registered
4th of 38
by date
Lead sponsor
4 of 38
Hoffmann-La Roche

Among the 38 studies testing tocilizumab in COVID-19, this one is the 7th largest by enrollment, is one of 34 that started in 2020, is one of 13 in phase 3, and was the 4th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 467 are open to participants now.

Browse COVID-19 studies →

Open to participants now

3 of the 38 studies testing tocilizumab in COVID-19 are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About tocilizumab

tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing tocilizumab in COVID-19, or all of them as a file.
02

Study summary

This study will evaluate the efficacy, safety, pharmacodynamics, and pharmacokinetics of tocilizumab (TCZ) compared with a matching placebo in combination with standard of care (SOC) in hospitalized patients with severe COVID-19 pneumonia.

03

Conditions studied

  • COVID-19 Pneumonia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Hospitalized with COVID-19 pneumonia confirmed per WHO criteria (including a positive PCR of any specimen; e.g., respiratory, blood, urine, stool, other bodily fluid) and evidenced by chest X-ray or CT scan
  • SPO2 \</=93% or PaO2/FiO2 \<300 mmHg

Exclusion criteria

Exclusion Criteria:

  • Known severe allergic reactions to TCZ or other monoclonal antibodies
  • Active tuberculosis (TB) infection
  • Suspected active bacterial, fungal, viral, or other infection (besides COVID-19)
  • In the opinion of the investigator, progression to death is imminent and inevitable within the next 24 hours, irrespective of the provision of treatments
  • Have received oral anti-rejection or immunomodulatory drugs (including TCZ) with the past 3 months
  • Participating in other drug clinical trials (participation in COVID-19 anti-viral trials may be permitted if approved by Medical Monitor)
  • Pregnant or breastfeeding, or positive pregnancy test in a pre-dose examination
  • Treatment with an drug within 5 half-lives or 30 days (whichever is longer) of randomization (investigational COVID-19 antivirals may be permitted if approved by Medial Monitor)
  • Any serious medical condition or abnormality of clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation in and completion of the study
  • (ALT) or aspartate aminotransferase (AST) > 10 x (ULN) detected within 24 hours at screening (per local lab)
  • (ANC) \< 1000/mL at screening (per local lab)
  • count \< 50,000/mL at screening (per local lab)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
452 participants (actual)

Study arms

  • Experimental
    Tocilizumab (TCZ) Arm

    Participants will receive 1 intravenous (IV) infusion of TCZ, dosed at 8 mg/kg, up to a maximum dose 800 mg. Up to 1 additional dose may be given if clinical symptoms worsen or show no improvement.

    Drug: Tocilizumab (TCZ)

  • Placebo comparator
    Placebo Arm

    Participants will receive 1 IV infusion of placebo matched to TCZ. Up to 1 additional dose may be given if clinical symptoms worsen or show no improvement.

    Drug: Placebo

Interventions

  • Participants will receive 1 dose of IV TCZ. 1 additional dose may be given if clinical symptoms worsen or show no improvement.

  • DrugPlacebo

    Participants will receive 1 dose of IV placebo matched to TCZ. Up to 1 additional dose may be given if clinical symptoms worsen or show no improvement.

06

What researchers measure

Primary outcomes

  1. Clinical Status Assessed Using a 7-Category Ordinal Scale at Day 28 (Week 4)

    Clinical status was assessed using a 7-category ordinal scale: 1. - Discharged (or "ready for discharge") 2. - Non- intensive care unit (ICU) hospital ward (or "ready for hospital ward") not requiring supplemental oxygen 3. - Non-ICU hospital ward (or "ready for hospital ward") requiring supplemental oxygen 4. - ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen 5. - ICU, requiring intubation and mechanical ventilation 6. - ICU, requiring extracorporeal membrane oxygenation (ECMO) or mechanical ventilation and additional organ support 7. - Death

    Time frame: Day 28

Secondary outcomes

  1. Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours

    Defined as time from first dose of study drug to at least two NEWS2 assessments with a score of \<=2 covering a span of at least 21.5 hours, with a maximum of 26.5 hours between the first and last of these assessments and no assessments with a score \>2 in between. If one of the components of the NEWS2 score was missing at a particular time point, then the NEWS2 score was not calculated. Participants who died were censored at Day 28.

    Time frame: Up to Day 28

  2. Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status

    Time to improvement for this outcome measure was defined as the days from the first dose of study drug to when at least a 2-category improvement in clinical status (based on a 7-category ordinal scale) is observed. Participants who died were censored at Day 28.

    Time frame: Up to Day 28

  3. Time to Hospital Discharge or "Ready for Discharge"

    Time to Hospital Discharge was defined as the time from the first dose of study drug to hospital discharge or "ready for discharge" (normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or \</=2L supplemental oxygen) Participants who died were censored at Day 28.

    Time frame: Up to Day 28

  4. Incidence of Mechanical Ventilation by Day 28

    Participants who died by Day 28 were assumed to have required mechanical ventilation.

    Time frame: Up to Day 28

  5. Ventilator-Free Days to Day 28

    Participants who died by Day 28 were assigned 0 ventilator-free days.

    Time frame: Up to Day 28

  6. Incidence of Intensive Care Unit (ICU) Stay by Day 28 (Week 4)

    Participants who died by Day 28 were assumed to have required an ICU stay.

    Time frame: Up to Day 28

  7. Duration of ICU Stay to Day 28 (Week 4)

    Participants who died by Day 28 were assigned a duration from the first dose of study drug to Day 28 at hour 23:59:59.

    Time frame: Up to Day 28

  8. Clinical Status Assessed Using a 7-Category Ordinal Scale at Day 14

    Clinical status was assessed using a 7-category ordinal scale: 1. - Discharged (or "ready for discharge") 2. - Non- intensive care unit (ICU) hospital ward (or "ready for hospital ward") not requiring supplemental oxygen 3. - Non-ICU hospital ward (or "ready for hospital ward") requiring supplemental oxygen 4. - ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen 5. - ICU, requiring intubation and mechanical ventilation 6. - ICU, requiring extracorporeal membrane oxygenation (ECMO) or mechanical ventilation and additional organ support 7. - Death

    Time frame: Day 14

  9. Time to Clinical Failure to Day 28 (Week 4)

    Time to clinical failure was defined as the number of days from the first dose of study drug to the first occurrence on study of death, mechanical ventilation, ICU admission, or study withdrawal prior to discharge, whichever occurs first.

    Time frame: Up to Day 28

  10. Mortality Rate at Day 28 (Week 4)

    Time frame: Day 28

  11. Time to Recovery to Day 28 (Week 4)

    Time to recovery was defined as the number of days from the first dose of study drug to hospital discharge or "ready for discharge" (normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or \</= 2L supplemental oxygen) or non-ICU hospital ward or "ready for hospital ward" not requiring supplemental oxygen. Participants who died were censored at Day 28.

    Time frame: Up to Day 28

  12. Duration of Supplemental Oxygen to Day 28 (Week 4)

    Participants who died by Day 28 were assigned a duration of 28 days of supplemental oxygen.

    Time frame: Up to Day 28

07

Results

Posted Jun 30, 2021

Participant flow

Participant flow — Overall Study
MilestonePlacebo Modified Intent-to-Treat (mITT) ArmTocilizumab (TCZ) mITT Arm
Started144294
Completed96190
Not completed48104
Withdrew: Withdrawal by subject410
Withdrew: Physician decision20
Withdrew: Other20
Withdrew: Lost to follow-up523
Withdrew: Death3571

Outcome measures

PrimaryClinical Status Assessed Using a 7-Category Ordinal Scale at Day 28 (Week 4)

Clinical status was assessed using a 7-category ordinal scale: 1. - Discharged (or "ready for discharge") 2. - Non- intensive care unit (ICU) hospital ward (or "ready for hospital ward") not requiring supplemental oxygen 3. - Non-ICU hospital ward (or "ready for hospital ward") requiring supplemental oxygen 4. - ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen 5. - ICU, requiring intubation and mechanical ventilation 6. - ICU, requiring extracorporeal membrane oxygenation (ECMO) or mechanical ventilation and additional organ support 7. - Death

Time frame:
Day 28
Reported as:
Number · Percentage of Participants
Clinical Status Assessed Using a 7-Category Ordinal Scale at Day 28 (Week 4)
Percentage of ParticipantsTocilizumab (TCZ) mITT ArmPlacebo Modified Intent-to-Treat (mITT) Arm
156.549.3
22.05.6
34.82.8
42.06.9
58.89.7
66.16.3
719.719.4
Statistical analysis
  • Tocilizumab (TCZ) mITT Arm vs Placebo Modified Intent-to-Treat (mITT) Arm · Van Elteren Test · p = 0.3600 · Median difference (final values): -1.0 · 95% CI -2.5 to 0.0
SecondaryTime to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours

Defined as time from first dose of study drug to at least two NEWS2 assessments with a score of \<=2 covering a span of at least 21.5 hours, with a maximum of 26.5 hours between the first and last of these assessments and no assessments with a score \>2 in between. If one of the components of the NEWS2 score was missing at a particular time point, then the NEWS2 score was not calculated. Participants who died were censored at Day 28.

Time frame:
Up to Day 28
Reported as:
Median · Days
Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours
DaysTocilizumab (TCZ) mITT ArmPlacebo Modified Intent-to-Treat (mITT) Arm
Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 HoursNA (NA to NA)NA (NA to NA)
Statistical analysis
  • Tocilizumab (TCZ) mITT Arm vs Placebo Modified Intent-to-Treat (mITT) Arm · Log Rank · p = 0.0443 · Hazard ratio (hr): 1.448 · 95% CI 1.01 to 2.08
SecondaryTime to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status

Time to improvement for this outcome measure was defined as the days from the first dose of study drug to when at least a 2-category improvement in clinical status (based on a 7-category ordinal scale) is observed. Participants who died were censored at Day 28.

Time frame:
Up to Day 28
Reported as:
Median · Days
Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status
DaysTocilizumab (TCZ) mITT ArmPlacebo Modified Intent-to-Treat (mITT) Arm
Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status14.0 (12.0 to 17.0)18.0 (15.0 to 28.0)
Statistical analysis
  • Tocilizumab (TCZ) mITT Arm vs Placebo Modified Intent-to-Treat (mITT) Arm · Log Rank · p = 0.0820 · Hazard ratio (hr): 1.263 · 95% CI 0.97 to 1.64
SecondaryTime to Hospital Discharge or "Ready for Discharge"

Time to Hospital Discharge was defined as the time from the first dose of study drug to hospital discharge or "ready for discharge" (normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or \</=2L supplemental oxygen) Participants who died were censored at Day 28.

Time frame:
Up to Day 28
Reported as:
Median · Days
Time to Hospital Discharge or "Ready for Discharge"
DaysTocilizumab (TCZ) mITT ArmPlacebo Modified Intent-to-Treat (mITT) Arm
Time to Hospital Discharge or "Ready for Discharge"20.0 (17.0 to 27.0)28.0 (20.0 to NA)
Statistical analysis
  • Tocilizumab (TCZ) mITT Arm vs Placebo Modified Intent-to-Treat (mITT) Arm · Log Rank · p = 0.0370 · Hazard ratio (hr): 1.350 · 95% CI 1.02 to 1.79
SecondaryIncidence of Mechanical Ventilation by Day 28

Participants who died by Day 28 were assumed to have required mechanical ventilation.

Time frame:
Up to Day 28
Reported as:
Number · Percentage of Participants
Incidence of Mechanical Ventilation by Day 28
Percentage of ParticipantsTocilizumab (TCZ) mITT ArmPlacebo Modified Intent-to-Treat (mITT) ArmTCZ - No Mechanical Ventilation at BaselinePlacebo - No Mechanical Ventilation at Baseline
Incidence of Mechanical Ventilation by Day 2854.4 (48.7 to 60.1)60.4 (52.4 to 68.4)27.9 (21.4 to 34.4)36.7 (26.7 to 46.6)
Statistical analysis
  • Tocilizumab (TCZ) mITT Arm vs Placebo Modified Intent-to-Treat (mITT) Arm · Cochran-Mantel-Haenszel · p = 0.0996 · Weighted % difference: -6.2 · 95% CI -13.8 to 1.4
  • TCZ - No Mechanical Ventilation at Baseline vs Placebo - No Mechanical Ventilation at Baseline · Cochran-Mantel-Haenszel · p = 0.1355 · Weighted % difference: -8.9 · 95% CI -20.7 to 3.0
SecondaryVentilator-Free Days to Day 28

Participants who died by Day 28 were assigned 0 ventilator-free days.

Time frame:
Up to Day 28
Reported as:
Median · Days
Ventilator-Free Days to Day 28
DaysTocilizumab (TCZ) mITT ArmPlacebo Modified Intent-to-Treat (mITT) Arm
Ventilator-Free Days to Day 2822.0 (18.0 to 28.0)16.5 (11.0 to 26.0)
Statistical analysis
  • Tocilizumab (TCZ) mITT Arm vs Placebo Modified Intent-to-Treat (mITT) Arm · Van Elteren test · p = 0.3202 · Median difference (final values): 5.5 · 95% CI -2.8 to 13.0
SecondaryIncidence of Intensive Care Unit (ICU) Stay by Day 28 (Week 4)

Participants who died by Day 28 were assumed to have required an ICU stay.

Time frame:
Up to Day 28
Reported as:
Number · Percentage of Participants
Incidence of Intensive Care Unit (ICU) Stay by Day 28 (Week 4)
Percentage of ParticipantsTocilizumab (TCZ) mITT ArmPlacebo Modified Intent-to-Treat (mITT) ArmTCZ - Not in ICU at BaselinePlacebo - Not in ICU at Baseline
Incidence of Intensive Care Unit (ICU) Stay by Day 28 (Week 4)66.0 (60.6 to 71.4)71.5 (64.2 to 78.9)21.3 (14.1 to 28.4)35.9 (24.2 to 47.7)
Statistical analysis
  • Tocilizumab (TCZ) mITT Arm vs Placebo Modified Intent-to-Treat (mITT) Arm · Cochran-Mantel-Haenszel · p = 0.1514 · Weighted % difference: -5.7 · 95% CI -13.7 to 2.2
  • TCZ - Not in ICU at Baseline vs Placebo - Not in ICU at Baseline · Cochran-Mantel-Haenszel · p = 0.0290 · Weighted % difference: -14.8 · 95% CI -28.6 to -1.0
SecondaryDuration of ICU Stay to Day 28 (Week 4)

Participants who died by Day 28 were assigned a duration from the first dose of study drug to Day 28 at hour 23:59:59.

Time frame:
Up to Day 28
Reported as:
Median · Days
Duration of ICU Stay to Day 28 (Week 4)
DaysTocilizumab (TCZ) mITT ArmPlacebo Modified Intent-to-Treat (mITT) Arm
Duration of ICU Stay to Day 28 (Week 4)9.8 (7.0 to 15.7)15.5 (8.7 to 25.5)
Statistical analysis
  • Tocilizumab (TCZ) mITT Arm vs Placebo Modified Intent-to-Treat (mITT) Arm · Van Elteren test · p = 0.0454 · Median difference (final values): -5.8 · 95% CI -15.0 to 2.9
SecondaryClinical Status Assessed Using a 7-Category Ordinal Scale at Day 14

Clinical status was assessed using a 7-category ordinal scale: 1. - Discharged (or "ready for discharge") 2. - Non- intensive care unit (ICU) hospital ward (or "ready for hospital ward") not requiring supplemental oxygen 3. - Non-ICU hospital ward (or "ready for hospital ward") requiring supplemental oxygen 4. - ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen 5. - ICU, requiring intubation and mechanical ventilation 6. - ICU, requiring extracorporeal membrane oxygenation (ECMO) or mechanical ventilation and additional organ support 7. - Death

Time frame:
Day 14
Reported as:
Number · Percentage of participants
Clinical Status Assessed Using a 7-Category Ordinal Scale at Day 14
Percentage of participantsTocilizumab (TCZ) mITT ArmPlacebo Modified Intent-to-Treat (mITT) Arm
139.829.9
26.14.9
36.511.1
47.17.6
514.616.0
612.617.4
713.313.2
Statistical analysis
  • Tocilizumab (TCZ) mITT Arm vs Placebo Modified Intent-to-Treat (mITT) Arm · Van Elteren test · p = 0.0548 · Median difference (final values): -1.0 · 95% CI -2.0 to 0.5
SecondaryTime to Clinical Failure to Day 28 (Week 4)

Time to clinical failure was defined as the number of days from the first dose of study drug to the first occurrence on study of death, mechanical ventilation, ICU admission, or study withdrawal prior to discharge, whichever occurs first.

Time frame:
Up to Day 28
Reported as:
Median · Days
Time to Clinical Failure to Day 28 (Week 4)
DaysTocilizumab (TCZ) mITT ArmPlacebo Modified Intent-to-Treat (mITT) Arm
Time to Clinical Failure to Day 28 (Week 4)NA (NA to NA)NA (21.0 to NA)
Statistical analysis
  • Tocilizumab (TCZ) mITT Arm vs Placebo Modified Intent-to-Treat (mITT) Arm · Log Rank · p = 0.1627 · Hazard ratio (hr): 0.790 · 95% CI 0.57 to 1.10
SecondaryMortality Rate at Day 28 (Week 4)
Time frame:
Day 28
Reported as:
Number · Percentage of Participants
Mortality Rate at Day 28 (Week 4)
Percentage of ParticipantsTocilizumab (TCZ) mITT ArmPlacebo Modified Intent-to-Treat (mITT) Arm
Mortality Rate at Day 28 (Week 4)19.7 (15.2 to 24.3)19.4 (13.0 to 25.9)
Statistical analysis
  • Tocilizumab (TCZ) mITT Arm vs Placebo Modified Intent-to-Treat (mITT) Arm · Cochran-Mantel-Haenszel · p = 0.9410 · Weighted % difference: 0.3 · 95% CI -7.6 to 8.2
SecondaryTime to Recovery to Day 28 (Week 4)

Time to recovery was defined as the number of days from the first dose of study drug to hospital discharge or "ready for discharge" (normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or \</= 2L supplemental oxygen) or non-ICU hospital ward or "ready for hospital ward" not requiring supplemental oxygen. Participants who died were censored at Day 28.

Time frame:
Up to Day 28
Reported as:
Median · Days
Time to Recovery to Day 28 (Week 4)
DaysTocilizumab (TCZ) mITT ArmPlacebo Modified Intent-to-Treat (mITT) Arm
Time to Recovery to Day 28 (Week 4)16.0 (12.0 to 21.0)24.0 (18.0 to NA)
Statistical analysis
  • Tocilizumab (TCZ) mITT Arm vs Placebo Modified Intent-to-Treat (mITT) Arm · Log Rank · p = 0.0528 · Hazard ratio (hr): 1.307 · 95% CI 1.00 to 1.72
SecondaryDuration of Supplemental Oxygen to Day 28 (Week 4)

Participants who died by Day 28 were assigned a duration of 28 days of supplemental oxygen.

Time frame:
Up to Day 28
Reported as:
Median · Days
Duration of Supplemental Oxygen to Day 28 (Week 4)
DaysTocilizumab (TCZ) mITT ArmPlacebo Modified Intent-to-Treat (mITT) Arm
Duration of Supplemental Oxygen to Day 28 (Week 4)26.5 (19.0 to 28.0)28.0 (26.0 to 28.0)
Statistical analysis
  • Tocilizumab (TCZ) mITT Arm vs Placebo Modified Intent-to-Treat (mITT) Arm · Van Elteren test · p = 0.0477 · Median difference (final values): -1.5 · 95% CI -9.0 to 0.5

Adverse events

Collected over 60 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo Arm (Safety-Evaluable Population)36/143 (25.2%)64/143 (44.8%)29/143 (20.3%)
Tocilizumab (TCZ) Arm (Safety-Evaluable Population)72/295 (24.4%)116/295 (39.3%)83/295 (28.1%)
Most frequent serious events
Showing 10 of 108
Most frequent serious events
EventPlacebo Arm (Safety-Evaluable Population)Tocilizumab (TCZ) Arm (Safety-Evaluable Population)
COVID-19 pneumoniaInfections and infestations20/14336/295
Septic shockInfections and infestations7/1437/295
COVID-19Infections and infestations2/14314/295
Respiratory failureRespiratory, thoracic and mediastinal disorders6/1435/295
Cardiac arrestCardiac disorders5/1434/295
Acute kidney injuryRenal and urinary disorders4/14310/295
PneumoniaInfections and infestations4/1437/295
SepsisInfections and infestations4/1433/295
BacteraemiaInfections and infestations3/1433/295
HypoxiaRespiratory, thoracic and mediastinal disorders3/1430/295
Most frequent other events
Most frequent other events
EventPlacebo Arm (Safety-Evaluable Population)Tocilizumab (TCZ) Arm (Safety-Evaluable Population)
Urinary tract infectionInfections and infestations5/14322/295
AnaemiaBlood and lymphatic system disorders10/14317/295
HypertensionVascular disorders3/14320/295
ConstipationGastrointestinal disorders8/14318/295
DiarrhoeaGastrointestinal disorders3/14318/295
PneumoniaInfections and infestations8/14310/295

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Placebo Modified Intent-to-Treat (mITT) ArmTocilizumab (TCZ) mITT ArmTotal
Mean60.6 ± 13.760.9 ± 14.660.8 ± 14.3
Sex: Female, Male
Sex: Female, Male(Participants)Placebo Modified Intent-to-Treat (mITT) ArmTocilizumab (TCZ) mITT ArmTotal
Female4389132
Male101205306
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo Modified Intent-to-Treat (mITT) ArmTocilizumab (TCZ) mITT ArmTotal
Hispanic or Latino4794141
Not Hispanic or Latino86181267
Unknown or Not Reported111930
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo Modified Intent-to-Treat (mITT) ArmTocilizumab (TCZ) mITT ArmTotal
American Indian or Alaska Native5813
Asian102838
Native Hawaiian or Other Pacific Islander538
Black or African American264066
White76176252
More than one race101
Unknown or Not Reported213960
08

Study locations

62 sites
  • University of California San Diego
    La Jolla, California 92093, United States
  • eStudySite
    La Mesa, California 91942, United States
  • David Geffen School of Medicine UCLA
    Los Angeles, California 90095, United States
  • Stanford University
    Stanford, California 94305, United States
  • Denver Health Medical Center
    Denver, Colorado 80204, United States
  • University of Miami Miller School of Medicine
    Miami, Florida 33136, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • Ochsner Clinic Foundation
    Baton Rouge, Louisiana 70809, United States
  • Baystate Health System
    Springfield, Massachusetts 01199, United States
  • Mayo Clinic - PPDS
    Rochester, Minnesota 55905, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Robert Wood Johnson University Hospital/Rutgers
    New Brunswick, New Jersey 08901, United States
  • James J Peters Veterans Administration Medical Center - NAVREF
    Bronx, New York 10468, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Cleveland Clinic Foundation; Pulmonary, Allergy & Critical Care Medicine
    Cleveland, Ohio 44195, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • Baylor St. Luke's Medical Center
    Houston, Texas 77030, United States
  • Ben Taub General Hospital - HCHD
    Houston, Texas 77030, United States
  • Intermountain Medical Group
    Saint George, Utah 84770, United States
  • Intermountain LDS Hospital
    Salt Lake City, Utah 84143, United States
  • Evergreen Health Infectious Disease
    Kirkland, Washington 98034, United States
  • Swedish Hospital Medical Center
    Seattle, Washington 98104, United States
  • Hamilton General Hospital; Pharmacy
    Hamilton, Ontario L8L 2X2, Canada
  • St. Joseph's Healthcare Hamilton
    Hamilton, Ontario L8N 4A6, Canada
  • University Health Network
    Toronto, Ontario M5G2M9, Canada
  • Clinical Research Institute of Montreal
    Montreal, Quebec H2W 1R7, Canada
  • Rigshospitalet Copenhagen University Hospital
    Copenhagen, DK-2100, Denmark
  • Hvidovre Hospital
    Hvidovre, DK-2650, Denmark
  • Odense Universitetshospital
    Odense C, 5000, Denmark
  • Sjællands Universitetshospital, Roskilde
    Roskilde, 4000, Denmark
  • Centre Hospitalier Departemental de Vendee
    La Roche Sur Yon, 85925, France
  • Centre Hospitalier et Universitaire de Limoges
    Limoges, 87042, France
  • Hôpital de La Croix Rousse
    Lyon, 69004, France
  • Hotel Dieu - Nantes
    Nantes, 44093, France
  • Hopital de la Pitie Salpetriere
    Paris, 75013, France
  • HOPITAL COCHIN university hospital
    Paris, 75014, France
  • CHRU de Tours, Pharmacie
    Tours, 37044, France
  • Universitatsklinikum Dusseldorf
    Dusseldorf, 40225, Germany
  • Medizinische Hochschule Hannover
    Hannover, 30625, Germany
  • Universitätsklinikum Köln; Innere Medizin I; Onkologie, Hämatologie
    Köln, 50931, Germany
  • LMU Klinikum der Universitat Munchen
    Munchen, 80337, Germany
  • Azienda Ospedaliera San Gerardo di Monza
    Monza MI, Lombardia 20900, Italy
  • Fondazione IRCCS Policlinico San Matteo di Pavia; S.S. Fisiopatologia Respiratoria
    Pavia, Lombardia 27100, Italy
  • Amphia Ziekenhuis
    Breda, 4819 EV, Netherlands
  • St. Antonius Ziekenhuis Nieuwegein
    Nieuwegein, 3435 CM, Netherlands
  • Erasmus MC
    Rotterdam, 3015 GD, Netherlands
  • Universitair Medisch Centrum Utrecht
    Utrecht, 3584 CX, Netherlands
  • Hospital Universitario de Bellvitge
    Hospitalet de Llobregat, Barcelona 08907, Spain
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital Clinic de Barcelona
    Barcelona, 08036, Spain
  • Hospital Universitario La Paz
    Madrid, 28034, Spain
  • Hospital Universitario Ramon y Cajal
    Madrid, 28034, Spain
  • Hospital General Universitario Gregorio Maranon
    Madrid, 28040, Spain
  • Hospital Universitario HM Sanchinarro-CIOCC
    Madrid, 28050, Spain
  • Greater Glasgow and Clyde Health Board
    Glasgow, G12 8TA, United Kingdom
  • Leeds Teaching Hospitals NHS Trust
    Leeds, LS9 7AU, United Kingdom
  • University College Hospital
    London, NW1 2BU, United Kingdom
  • Royal Free Hospital
    London, NW3 2QS, United Kingdom
  • St George's Clinical Research Facility
    London, SW17 0RE, United Kingdom
  • Imperial College London
    London, W6 8RF, United Kingdom
  • North Manchester General Hospital
    Manchester, M8 5RB, United Kingdom
09

References and documents

Publications

  • Rosas IO, Brau N, Waters M, Go RC, Malhotra A, Hunter BD, Bhagani S, Skiest D, Savic S, Douglas IS, Garcia-Diaz J, Aziz MS, Cooper N, Youngstein T, Sorbo LD, Zerda DJ, Ustianowski A, Gracian AC, Blyth KG, Carratala J, Francois B, Benfield T, Haslem D, Bonfanti P, van der Leest CH, Rohatgi N, Wiese L, Luyt CE, Bauer RN, Cai F, Lee IT, Matharu B, Metcalf L, Wildum S, Graham E, Tsai L, Bao M. Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA). EClinicalMedicine. 2022 May;47:101409. doi: 10.1016/j.eclinm.2022.101409. Epub 2022 Apr 21. PubMed 35475258 ↗
  • Tom J, Bao M, Tsai L, Qamra A, Summers D, Carrasco-Triguero M, McBride J, Rosenberger CM, Lin CJF, Stubbings W, Blyth KG, Carratala J, Francois B, Benfield T, Haslem D, Bonfanti P, van der Leest CH, Rohatgi N, Wiese L, Luyt CE, Kheradmand F, Rosas IO, Cai F. Prognostic and Predictive Biomarkers in Patients With Coronavirus Disease 2019 Treated With Tocilizumab in a Randomized Controlled Trial. Crit Care Med. 2022 Mar 1;50(3):398-409. doi: 10.1097/CCM.0000000000005229. Erratum In: Crit Care Med. 2023 Aug 01;51(8):e177. doi: 10.1097/CCM.0000000000005960. PubMed 34612846 ↗
  • Rosas IO, Brau N, Waters M, Go RC, Hunter BD, Bhagani S, Skiest D, Aziz MS, Cooper N, Douglas IS, Savic S, Youngstein T, Del Sorbo L, Cubillo Gracian A, De La Zerda DJ, Ustianowski A, Bao M, Dimonaco S, Graham E, Matharu B, Spotswood H, Tsai L, Malhotra A. Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia. N Engl J Med. 2021 Apr 22;384(16):1503-1516. doi: 10.1056/NEJMoa2028700. Epub 2021 Feb 25. PubMed 33631066 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform https://vivli.org. Further details on Roche's criteria for eligible studies are available here: https://vivli.org. For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here: (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2020 to primary completion in Jun 2020, 2 months.

Results were first posted in Jun 2021, 1 year after primary completion.

Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 2 months is below that.

Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 4 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2020
First posted
Mar 25, 2020
StartActual
Apr 3, 2020
Primary completionActual
Jun 24, 2020
CompletionActual
Jul 28, 2020
Results first posted
Jun 30, 2021
Last update
Jun 30, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 30, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04320615
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Mar 25, 2020
Start date
Apr 3, 2020
Primary completion
Jun 24, 2020
Completion
Jul 28, 2020
Results posted
Jun 30, 2021
Last update
Jun 30, 2021

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tocilizumab

Start the discussion